COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.

Autor: Strohbehn GW; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Heiss BL; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Rouhani SJ; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Trujillo JA; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Yu J; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Kacew AJ; Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA., Higgs EF; Committee on Immunology, The University of Chicago, Chicago, Illinois, USA., Bloodworth JC; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Cabanov A; Committee on Immunology, The University of Chicago, Chicago, Illinois, USA., Wright RC; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Koziol AK; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Weiss A; Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois, USA., Danahey K; Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois, USA.; Center for Research Informatics, The University of Chicago, Chicago, Illinois, USA., Karrison TG; Department of Public Health Policy, The University of Chicago, Chicago, Illinois, USA., Edens CC; Department of Medicine, Section of Rheumatology, The University of Chicago, Chicago, Illinois, USA.; Department of Pediatrics, Section of Rheumatology, The University of Chicago, Chicago, Illinois, USA., Bauer Ventura I; Department of Medicine, Section of Rheumatology, The University of Chicago, Chicago, Illinois, USA., Pettit NN; Department of Pharmacy, The University of Chicago, Chicago, Illinois, USA., Patel BK; Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois, USA., Pisano J; Department of Medicine, Section of Infectious Diseases and Global Health, The University of Chicago, Chicago, Illinois, USA., Strek ME; Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois, USA., Gajewski TF; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA., Ratain MJ; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.; Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois, USA., Reid PD; Department of Medicine, Section of Rheumatology, The University of Chicago, Chicago, Illinois, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Mar; Vol. 109 (3), pp. 688-696. Date of Electronic Publication: 2020 Dec 10.